<DOC>
	<DOCNO>NCT02432664</DOCNO>
	<brief_summary>The purpose study investigate extent new study drug tolerate human . The study divide 3 part ( Part III optional may go ahead depend result Parts I II ) . The volunteer enrol one part study . In part I II volunteer receive active study drug placebo . In part I volunteer receive single dose one eight plan escalate dose level . In part II volunteer receive 4 plan dose level base result obtain Part 1 study , option include additional dosing group . In optional part III volunteer receive ODM-108 already register drug interaction drug study . It investigate quickly extent study drug absorb eliminate body ( call pharmacokinetics ) . In addition , part I II effect compound sensation pain cognition ( activity think , understand , learn , remember ) investigate ( call pharmacodynamics ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Pharmacodynamic Effects ODM-108 : Healthy Male Volunteers</brief_title>
	<detailed_description>This first time compound give human . The study take place approve Independent Ethics Committee .</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Inclusion Criteria applicable Parts I III : Written inform consent . Good general health Males 18 55 year ( inclusive ) . Body mass index ( BMI ) 1830 kg/m2 inclusive Weight 5595 kg ( inclusive ) . Participants female partner childbearing potential must adhere proper form contraception . Subjects light colour skin . A predictable poor compliance inability understand comply protocol , instruction protocol restriction communicate well investigator . Vulnerable subject . Veins unsuitable repeat venipuncture . Evidence clinically relevant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological , urogenital psychiatric disease judge investigator . Medical history relevant psychiatric disorder evidence clinically relevant neuropsychiatric disease . Suicidal ideation 6 month screen current risk suicide base investigator judgement . History hypersensitivity drug excipients . Any condition require regular concomitant medication . Intake medication could affect outcome study . History Alcoholism . Inability refrain use nicotinecontaining product 48 h stay study centre . History drug abuse positive drug screen . Blood donation loss clinically relevant amount blood within 2 month screen visit . Abnormal 12lead ECG Heart rate &lt; 40 bpm &gt; 100 bpm screening . Systolic BP &lt; 90 mmHg &gt; 140 mmHg , diastolic BP &lt; 45 mmHg &gt; 90 mmHg , orthostatic hypotension decrease equal 20 mmHg systolic BP , decrease equal 10 mmHg diastolic BP screening . Abnormal 24h Holter clinical relevance screening . Positive serology HIV antibody ( HIVAb ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) . Thrombocytes neutrophils count &lt; low limit normal range . alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase total bilirubin &gt; upper limit normal ( ULN ) . Any abnormal value laboratory , vital sign , physical examination , may , opinion investigator interfere interpretation test result cause health risk subject . Participation investigational drug study within 2 month entry study . An employee direct relative employee CRO sponsor . Any condition opinion investigator would interfere evaluation result constitute health risk subject . Additional exclusion criterion Part I II : An abnormal screening EEG . A history skin condition bad reaction exposure capsaicin mustard oil . Following intradermal injection capsaicin ( 100 Î¼g ) screen visit , area hyperalgesia &lt; 10 cm2 , area flare &lt; 10 cm2 15 min . Additional exclusion criterion Part II : Use nicotinecontaining product within previous 3 month . The following additional exclusion criterion check Part I II : Inability complete either Digital Symbol Substitution Test ( DSST ) ( Part I ) psychomotor test battery ( Part II ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>